Assertio Holdings Inc
NASDAQ:ASRT
Assertio Holdings Inc
Revenue
Assertio Holdings Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Assertio Holdings Inc
NASDAQ:ASRT
|
Revenue
$152.1m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
1%
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$85.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$55.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
1%
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$35.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
Assertio Holdings Inc
Revenue Breakdown
Breakdown by Geography
Assertio Holdings Inc
Breakdown by Segments
Assertio Holdings Inc
Total Revenue:
152.1m
USD
|
Product Sales, Net:
149.5m
USD
|
Indocin Products:
87.2m
USD
|
Rolvedon:
18.2m
USD
|
Otrexup:
12m
USD
|
Sympazan:
9.9m
USD
|
Sprix:
9.2m
USD
|
Cambia:
8.1m
USD
|
Royalties And Milestones:
2.4m
USD
|
Other Revenue:
200k
USD
|
See Also
What is Assertio Holdings Inc's Revenue?
Revenue
152.1m
USD
Based on the financial report for Dec 31, 2023, Assertio Holdings Inc's Revenue amounts to 152.1m USD.
What is Assertio Holdings Inc's Revenue growth rate?
Revenue CAGR 10Y
1%
Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Assertio Holdings Inc have been 13% over the past three years , -13% over the past five years , and 1% over the past ten years .